Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Helen W Boucher"'
Autor:
Shira Doron, Robin R. Ingalls, Anne Beauchamp, Jesse S. Boehm, Helen W. Boucher, Linda H. Chow, Linda Corridan, Katey Goehringer, Doug Golenbock, Liz Larsen, David Lussier, Marcia Testa, Andrea Ciaranello
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 11, Pp 100452- (2021)
Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in K–12 schools was rare during in 2020–2021; few studies included Centers for Disease Control and Prevention (CDC)-recommended screening of asymptomatic individua
Externí odkaz:
https://doaj.org/article/90a57780293340a2b9be6f4eb595aacd
Autor:
Tori Kinamon, Ramya Gopinath, Ursula Waack, Mark Needles, Daniel Rubin, Deborah Collyar, Sarah B Doernberg, Scott Evans, Toshimitsu Hamasaki, Thomas L Holland, Jessica Howard-Anderson, Henry Chambers, Vance G Fowler, Sumati Nambiar, Peter Kim, Helen W Boucher
Publikováno v:
Clinical Infectious Diseases.
Background Desirability of outcome ranking (DOOR) is a novel approach to clinical trial design that incorporates safety and efficacy assessments into an ordinal ranking system to evaluate overall outcomes of clinical trial participants. Here, we deri
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Jayanti Gupta, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher
Publikováno v:
Clinical Infectious Diseases.
Autor:
Mohamad Yasmin, Laura J Rojas, Steven H Marshall, Andrea M Hujer, Anna Cmolik, Emma Marshall, Helen W Boucher, Alejandro J Vila, Maxime Soldevila, Seydina M Diene, Jean-Marc Rolain, Robert A Bonomo
Publikováno v:
Open Forum Infect Dis
Open Forum Infectious Diseases
Open Forum Infectious Diseases, 2023, 10 (2), pp.ofad014. ⟨10.1093/ofid/ofad014⟩
Open Forum Infectious Diseases
Open Forum Infectious Diseases, 2023, 10 (2), pp.ofad014. ⟨10.1093/ofid/ofad014⟩
BackgroundElizabethkingia anophelis is an emerging Gram-negative nonlactose fermenter in the health care setting, where it causes life-threatening infections in immunocompromised patients. We aimed to characterize the molecular mechanisms of antimicr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb9e88a69621f9d08160de3f0eba0f9f
https://europepmc.org/articles/PMC9938519/
https://europepmc.org/articles/PMC9938519/
Autor:
Ahmed Ullah Mishuk, Jeffrey R Strich, Sarah Warner, Junfeng Sun, Seidu Malik, Alexander Lawandi, Maiko Kondo, Michael J Satlin, Aditya Chandorkar, Emily L Heil, Megan K Morales, Anisha Mathur, Joseph Timpone, Darcy Wooten, Daniel Sweeney, Jonathan Pan, Jillian Raybould, Stephanie Bonne, Roberto Colindres, Helen W Boucher, Sara Buckman, Daisuke Furukawa, Daniel Uslan, Samuel F Hohmann, Sameer S Kadri
Publikováno v:
Open Forum Infectious Diseases. 9
Background Ceftazidime-avibactam (caz-avi), a novel β-lactam/β-lactamase inhibitor, is commonly utilized for carbapenem-resistant gram-negative infections (CR-GNI). However, the benefits vs risks of combining caz-avi with other agents are unclear.
Autor:
Tori Kinamon, Ramya Gopinath, Ursula Waack, Mark Needles, Daniel Rubin, Deborah Collyar, Sarah B Doernberg, Scott R Evans, Toshimitsu Hamasaki, Thomas L Holland, Jessica Howard-Anderson, Henry Chambers, Vance G Fowler, Sumathi Nambiar, Peter Kim, Helen W Boucher
Publikováno v:
Open Forum Infectious Diseases. 9
Background Desirability of outcome ranking (DOOR) uses an ordinal ranking system to evaluate global outcomes in clinical trial participants by incorporating safety and efficacy assessments into a single endpoint. In this study, we developed and appli
Autor:
David E. Greenberg, Amanda Jezek, Kevin Outterson, Amila K. Nanayakkara, Vance G. Fowler, Helen W. Boucher
Publikováno v:
CA: A Cancer Journal for Clinicians. 71:488-504
Infection is the second leading cause of death in patients with cancer. Loss of efficacy in antibiotics due to antibiotic resistance in bacteria is an urgent threat against the continuing success of cancer therapy. In this review, the authors focus o
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Background There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens th
Autor:
Nicholas A. Kartsonis, Antoine Roquilly, Robert W. Tipping, Luke F Chen, Aileen David-Wang, Richard G. Wunderink, Joan R. Butterton, Daniel Gonzalez, Jiejun Du, Munjal Patel, Keith S Kaye, Katherine Young, Ivan Titov, Michelle L Brown, Maria C Losada, Amanda Paschke, Helen W. Boucher, Matthew L. Rizk
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating h
Autor:
Robin R. Ingalls, Katey Goehringer, Anne Beauchamp, Liz Larsen, Doug T. Golenbock, Andrea L. Ciaranello, David Lussier, Jesse S. Boehm, Helen W. Boucher, Shira Doron, Linda Corridan, Marcia A. Testa, Linda H. Chow
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 11, Pp 100452-(2021)
Cell Reports Medicine
Cell Reports Medicine
SARS-CoV-2 transmission in K-12 schools was rare during in 2020-2021; few studies included CDC-recommended screening of asymptomatic individuals. We conduct a prospective observational study of SARS-CoV-2 screening in a mid-sized suburban public scho